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A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4–C6. The tumor 
recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. 
Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the 
tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection 
is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. 
Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for 
treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of re-
currence.
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Introduction
Giant cell tumor (GCT) of bone is a primary tumor that 
commonly occurs in the epiphyses of long bones, and 
most frequently in the distal end of the femur [1]. GCT 
seldom occurs in the vertebrae above the sacrum and its 
occurrence in the cervical spine is rare [2]. GCT of bone 
is categorized as benign, but it has a tendency to local ag-
gressiveness and with recurrence leading to difficulty in 
full recovery. We describe a case of recurrent GCT in the 
cervical spine that was managed using denosumab.
Case Report
A 43-year-old man presented with a 2-month history of 
progressive neck pain. Neurological examination results 
were normal. X-ray imaging and computed tomography 
(CT) of his cervical spine revealed an osteolytic change in 
the vertebral body of C5 (Fig. 1). The intervertebral disc 
space was well preserved. On magnetic resonance imag-
ing, the C5 vertebral body showed hypointense signals on 
T1-weighted imaging (T1WI) and hyperintense signals on 
T2WI (Fig. 2). Signal change was also seen in the anterior 
tubercle and left transverse foramen, but not in laminae.
Daisuke Kajiwara et al.554 Asian Spine J 2016;10(3):553-557
A biopsy was taken under general anesthesia, and the 
tumor was histopathologically confirmed to be a GCT 
of the bone and was resected via an anterior cervical ap-
proach. Bilateral vertebral arteries were not involved, and 
were preserved. After high-speed burring of the tumor 
margin, C4–C6 fusion was performed with an iliac crest 
bone graft and anterior cervical plate (Fig. 3). The post-
operative course was unremarkable. The patient’s neck 
pain was resolved one week after surgery, and he was dis-
charged from hospital 2 weeks after surgery with normal 
neurological examination results.
Approximately 9 months later, the patient had neck 
pain similar to his preoperative symptoms, and without 
any neurological deficit. CT of the cervical spine showed 
an osteolytic lesion of the bilateral articular processes, 
and we diagnosed it as recurrent GCT (Fig. 4). The pa-
tient did not wish to undergo the second surgery that we 
considered. We offered denosumab treatment, which he 
accepted. Denosumab (120 mg; Amgen, Thousand Oaks, 
CA, USA) was administered subcutaneously on days 1, 8, 
15, and 29, and subsequently every 4 weeks. A vitamin D 
and a calcium supplement were taken orally to avoid hy-
pocalcemia. No major complications were associated with 
denosumab administration. Two months after beginning 
treatment, significant bone formation was confirmed at 
the site of recurrence (Fig. 5). His symptoms at the time 
of recurrence gradually resolved. Eighteen months after 
beginning treatment, formed bone was maintained, and 
no evidence of recurrence was seen on CT imaging (Fig. 6). 
He continued to tolerate the treatment without any symp-
toms suggestive of recurrence.
Fig. 2. Preoperative cervical magnetic resonance imaging. C5 vertebral 
body (▲) with hypointense signals on (A) T1-weighted imaging (T1WI) 
and hyperintense signals on (B) T2WI.
A B
Fig. 3. Imaging findings after surgery. (A) X-ray image showed that 
C4–C6 fusion was performed using an iliac crest bone graft and an-
terior cervical plate. (B) Axial computed tomography showed that the 
vertebral body and the left anterior tubercle of C5 were completely 
resected.
A B
Fig. 4. Computed tomography at recurrence. Axial computed 
tomography of the C5 vertebral body showed an osteolytic le-
sion of the bilateral articular processes (▲).
Fig. 1. Imaging findings at the initial visit. (A) X-ray image and (B) 
computed tomography of the cervical spine revealing the presence of 
osteolytic change in the C5 vertebral body.
A B
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Discussion
In this study, we used denosumab to treat a recurrent 
GCT of the cervical spine and showed that the treatment 
was effective, both clinically and radiologically, and with 
no adverse side effects noted. GCTs account for 4%–5% 
of primary bone tumors and about 20% of benign bone 
tumors [3]. The incidence of GCT in the spine above the 
sacrum is estimated at between 0.1% and 0.25% of all 
bone tumors [4]. GCT may exhibit aggressiveness, often 
associated with enhanced osteolysis with a soap bubble-
like multilocular appearance, and the development of lung 
metastasis [5].
The GCT consists of osteoclast-like multinucleated gi-
ant cells, round monocyte-like cells, and spindle-shaped 
fibroblast-like stromal cells [6]. Osteoclast-like giant 
cells express receptor activator of nuclear factor kappa-b 
(RANK) and fibroblast-like stromal cells express RANK-
ligand (RANKL). The GCT pathogenesis may be the 
result of an imbalance in the RANK–RANKL pathway 
[1]. The optimal management of GCTs is complete tumor 
resection with a wide margin [7]. However, management 
of patients with cervical GCT is not easy because of its 
anatomical peculiarity, where complete wide resection is 
normally difficult to achieve [4]. Several cases of cervical 
tumor recurrence after subtotal excision have been re-
ported [8-10]. 
To date, there is no consensus for the treatment of 
cervical GCT [10]. Because our patient did not wish to 
undergo additional surgery, we considered other options 
such as radiation therapy, embolization, or chemotherapy. 
However, these options are controversial considering 
their advantages and disadvantages [11-17]. Denosumab, 
a monoclonal antibody to RANKL, has been used for 
the treatment of GCT with good results: a phase II study 
of denosumab demonstrated a tumor response in 30/35 
patients [18], and the investigators established the thera-
peutic potential of denosumab to inhibit progressive bone 
destruction in unsalvageable GCT. Post-treatment tissue 
samples from 16 patients showed spindle-shaped cell-
dense stroma were replaced with less cellular stroma in the 
tumor central area and woven bone transitioned to nor-
mal lamellar bone at the peripheral margin of the tumor.
Denosumab was effective for our treatment of recurrent 
GCT without any side effects. The clinical symptoms dis-
appeared after commencing of the treatment, and cervical 
X-ray imaging showed bone formation in the area sur-
rounding the relapse, similar to the phase II study findings.
Some adverse effects, such as hypocalcemia (5%), osteo-
necrosis of the jaw (1%), and atypical femoral fractures are 
associated with denosumab use [19]. Therefore, routine 
monitoring of calcium levels in the blood is necessary, and 
calcium and vitamin D supplementation as required. Ad-
ditionally, regular dental examination is recommended. 
The incidence of atypical femoral fractures associated with 
denosumab use remains incompletely understood [20,21]. 
X-ray examination of the femur is recommended if the 
patient complains of dull pain in the thighs. Furthermore, 
Fig. 5. Computed tomography after initiation of denosumab 
therapy. Significant bone formation is seen at the area of the 
tumor recurrence at the C5 vertebral body (▲).
Fig. 6. Computed tomography imaging at the final visit. Bone 
formation resulting from administration of denosumab was 
maintained, and local repeat recurrence was not observed.
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Kobayashi and Setsu [22] reported a case in which scleros-
ing bands were seen in almost all of the radiographs of the 
metaphysis after treatment with denosumab. Considering 
these side effects, long-term administration of denosumab 
should be avoided.
Currently, however, there is no defined endpoint for use 
of denosumab as a treatment for GCT [23], and there have 
been cases of recurrent GCT following the cessation of de-
nosumab therapy [22,24]. In light of the previous reports 
showing that the mean time to recurrence was about two 
years after surgery [25,26], we think that the 18-month 
follow-up period of our case is still insufficient and that it 
would be appropriate to administer denosumab with care-
ful observation for at least two years after recurrence.
Recently, some GCT cases have been described in 
which neoadjuvant denosumab therapy before spine sur-
gery achieved good results [27,28]. Although we obtained 
a good result using denosumab after a recurrence of GCT, 
it is necessary to consider the appropriate timing of ad-
ministration before and after surgery.
In conclusion, we consider that if possible, complete 
resection is optimal for recurrent cervical GCT, but that 
denosumab is an efficacious treatment option as shown in 
the present case. 
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